Celgene Corp (CELG) 144.12 $CELG
Why Agios Pharmaceuticals Inc. Shares Flopped
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 5:08PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Agios Pharmaceuticals , a clinical-stage...
Final Glance: Biotechnology companies
AP - Thu May 08, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Investor's Corner: How To Use The Big Cap 20
at Investor's Business Daily - Thu May 08, 3:09PM CDT
As IBD stock screens go, the IBD Big Cap 20 is of a different stripe. A primary focus on large-capitalization stocks distinguishes it from the high-growth slant of the IBD 50 or Your Weekly Review. But that doesn't mean that the IBD Big Cap 20, which...
Midday Glance: Biotechnology companies
AP - Thu May 08, 12:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Thu May 08, 9:48AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Fear Not, Biotech Stock 'Correction' Is Not a Bursting Bubble
at The Street - Wed May 07, 9:18AM CDT
We're not experiencing a dot-com-esque implosion in biotech stocks, no matter how loud the bears scream.
What Does Celgene's May 15 Markman Hearing Mean to You?
at The Street - Wed May 07, 9:11AM CDT
Celgene faces a big hearing over patents on its franchise product. Here's what investors need to know.
Celgene Prices $2.5 Billion of Senior Unsecured Notes
Business Wire - Wed May 07, 6:31AM CDT
Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $2,500 million. Of these notes, $500 million will mature in 2019 and will bear interest at an annual rate of 2.250 percent; $1,000 million will mature in 2024 and will bear interest at an annual rate of 3.625 percent and $1,000 million will mature in 2044 and will bear interest at an annual rate of 4.625 percent. The 2.250 percent notes due 2019, the 3.625 percent notes due 2024 and the 4.625 percent notes due in 2044 were priced to yield 2.303 percent, 3.666 percent and 4.647 percent, respectively.
Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
PR Newswire - Tue May 06, 8:15AM CDT
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:
Celgene Announces Offering of Senior Unsecured Notes
Business Wire - Tue May 06, 7:31AM CDT
Celgene Corporation (NASDAQ:CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.
Is Merrimack Pharmaceuticals Worth More Than $700 Million?
Todd Campbell, The Motley Fool - Motley Fool - Mon May 05, 8:30AM CDT
When patients are diagnosed with diseases like pancreatic cancer where survival is measured in months, not years, any advance is an important one. That's why oncologists and patients are watching Merrimack Pharmaceuticals . Merrimack just...
Quarterly Earnings Releases, Social Initiatives, and Upcoming Conferences - Analyst Notes on Merck, WellPoint, UnitedHealth, Forest and Celgene
PR Newswire - Mon May 05, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), WellPoint Inc. (NYSE: WLP), UnitedHealth Group Inc. (NYSE: UNH), Forest Laboratories Inc. (NYSE: FRX) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2020-100free.
1 Biotech's Earnings the Market Got Completely Wrong
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun May 04, 2:03PM CDT
In this segment from Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass look at the recent earnings report from biotech company Celgene , to sift out the vital numbers that investors need to know. The guys...
Why Agios Pharmaceuticals Inc. Shares Flopped
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 5:08PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Agios Pharmaceuticals , a clinical-stage...
Final Glance: Biotechnology companies
AP - Thu May 08, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Investor's Corner: How To Use The Big Cap 20
at Investor's Business Daily - Thu May 08, 3:09PM CDT
As IBD stock screens go, the IBD Big Cap 20 is of a different stripe. A primary focus on large-capitalization stocks distinguishes it from the high-growth slant of the IBD 50 or Your Weekly Review. But that doesn't mean that the IBD Big Cap 20, which...
Midday Glance: Biotechnology companies
AP - Thu May 08, 12:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Thu May 08, 9:48AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Fear Not, Biotech Stock 'Correction' Is Not a Bursting Bubble
at The Street - Wed May 07, 9:18AM CDT
We're not experiencing a dot-com-esque implosion in biotech stocks, no matter how loud the bears scream.
What Does Celgene's May 15 Markman Hearing Mean to You?
at The Street - Wed May 07, 9:11AM CDT
Celgene faces a big hearing over patents on its franchise product. Here's what investors need to know.
Celgene Prices $2.5 Billion of Senior Unsecured Notes
Business Wire - Wed May 07, 6:31AM CDT
Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $2,500 million. Of these notes, $500 million will mature in 2019 and will bear interest at an annual rate of 2.250 percent; $1,000 million will mature in 2024 and will bear interest at an annual rate of 3.625 percent and $1,000 million will mature in 2044 and will bear interest at an annual rate of 4.625 percent. The 2.250 percent notes due 2019, the 3.625 percent notes due 2024 and the 4.625 percent notes due in 2044 were priced to yield 2.303 percent, 3.666 percent and 4.647 percent, respectively.
Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
PR Newswire - Tue May 06, 8:15AM CDT
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:
Celgene Announces Offering of Senior Unsecured Notes
Business Wire - Tue May 06, 7:31AM CDT
Celgene Corporation (NASDAQ:CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.
Is Merrimack Pharmaceuticals Worth More Than $700 Million?
Todd Campbell, The Motley Fool - Motley Fool - Mon May 05, 8:30AM CDT
When patients are diagnosed with diseases like pancreatic cancer where survival is measured in months, not years, any advance is an important one. That's why oncologists and patients are watching Merrimack Pharmaceuticals . Merrimack just...
Quarterly Earnings Releases, Social Initiatives, and Upcoming Conferences - Analyst Notes on Merck, WellPoint, UnitedHealth, Forest and Celgene
PR Newswire - Mon May 05, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), WellPoint Inc. (NYSE: WLP), UnitedHealth Group Inc. (NYSE: UNH), Forest Laboratories Inc. (NYSE: FRX) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2020-100free.
1 Biotech's Earnings the Market Got Completely Wrong
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun May 04, 2:03PM CDT
In this segment from Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass look at the recent earnings report from biotech company Celgene , to sift out the vital numbers that investors need to know. The guys...
